Theralase Technologies announced its lead cancer drug TLD-1433 showed preclinical effectiveness against a deadly form of brain cancer when activated with X-rays.

Theralase Technologies (TSXV:TLT; OTCQX:TLTFF) announced its lead cancer drug TLD-1433 showed preclinical effectiveness against a deadly form of brain cancer when activated with X-rays.
As quoted in the press release:

According to the American Brain Tumor Association:
“[GlioBlastoma Multiforme] GBM represents 14.9% of all primary brain tumors and 55.4% of all gliomas. GBM has the highest number of cases of all malignant tumors, with an estimated 12,390 new cases predicted in 2017.”
In research conducted by Pavel Kaspler, Ph.D., Research Scientist and Manunatha Munegowda, Ph.D., Research Scientist, both of Theralase, under the direction of Arkady Mandel, MD, Ph.D., D.Sc., Chief Scientific Officer, Theralase, Rutherrin® has been demonstrated to possess the ability to selectively uptake into malignant GBM tumor cells (demonstrated in a rat RG2 cell-induced brain tumor model) over 22 times greater than in normal brain tissue, fulfilling criteria 1 above.

Click here to read the full press release.

Source: www.accesswire.com

cancer cancer drug cells chief scientific officer tumors Biotech Investing